Akorn, Inc. (NASDAQ:AKRX)
Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. They specialize in difficult-to-manufacture sterile and non-sterile dosage forms including: ophthalmics, injectables, oral liquids, otics, topicals, inhalants, and nasal sprays. Akorn markets its products to retail pharmacies, ophthalmologists, optometrists, physicians, veterinarians, hospitals, clinics, wholesalers, distributors, group purchasing organizations, and government agencies. Their strategy is focused on continuing to strengthen our leadership position in the development and marketing of specialized generic and branded pharmaceuticals, over-the-counter (OTC) drug products and animal health products.
Akorn, Inc. (NASDAQ:AKRX)’s Financial Overview
Akorn, Inc. (NASDAQ) declined -0.49% yesterday to close its trading session at $4.07. The company has 1 year Price Target of $8. Akorn, Inc. has 52-Week high of $32.97 and 52-Week Low of $3.14. The stock touched its 52-Week High on 32.97 and 52-Week Low on 3.14. The stock traded with the volume of 2.53 Million shares yesterday. The firm shows the market capitalization of $494.91 Million.
Akorn, Inc. (NASDAQ) reported its last quarterly earnings on 9/29/2018 where the firm reported its Actual EPS of $-0.06/share against the analyst consensus estimate of $0.07/share. The difference between the actual and expected EPS is $-0.13 a share with a surprise factor of -185.7%.
The firm is trading with SMA20 of 8.46 Percent, SMA50 of -13.91 Percent and SMA200 of -64.55 percent. Akorn, Inc. has P/S value of 0.68 while its P/B value stands at 0.78. Similarly, the company has Return on Assets of -13.9 percent, Return on Equity of -33.4 percent and Return on Investment of -0.6 Percent. The company shows Gross Margin and Operating Margin of 41.8 percent and -42.6 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 2.7 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 5 analysts offering 12-month price forecasts for Akorn Inc have a median target of 7.00, with a high estimate of 11.00 and a low estimate of 6.00. The median estimate represents a +71.99% increase from the last price of 4.07.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing novel therapies for the management of pain and other central nervous system disorders. Its product candidate portfolio consists of AXS-02 and AXS-05 which are in clinical trial stage. Axsome Therapeutics, Inc. is based in New York.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)’s Financial Outlook
The 4 analysts offering 12-month price forecasts for Axsome Therapeutics Inc have a median target of 18.00, with a high estimate of 45.00 and a low estimate of 15.00. The median estimate represents a +116.09% increase from the last price of 8.33.
Axsome Therapeutics, Inc. is estimated to report earnings on 03/06/2019. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.33. The reported EPS for the same quarter last year was $-0.28.
According to Zacks Investment Research, Axsome Therapeutics, Inc. has a Consensus Recommendation of 1. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged 2.21% and closed its last trading session at $8.33. The company has the market capitalization of $240.82 Million. The stock has 52-week high of $9.16 and 52-Week low of $1.94. The firm touched its 52-Week high on 9.16 and 52-Week low on 1.94. The company has volume of 467418 shares. The company has a total of 28.91 Million shares outstanding.
Axsome Therapeutics, Inc. (NASDAQ) in the last quarter reported its actual EPS of $-0.31/share where the analyst estimated EPS was $-0.29/share. The difference between the actual and Estimated EPS is $-0.02. This shows a surprise factor of -6.9 percent.
The company has YTD performance of 195.39 percent. Beta for Axsome Therapeutics, Inc. stands at 0 while its ATR (average true range) is 0.82. The company has Weekly Volatility of 7.84%% and Monthly Volatility of 13.96%%.
Axsome Therapeutics, Inc. has distance from 20-day Simple Moving Average (SMA20) of 19.86%, Distance from 50-Day Simple Moving Average of 84.64 percent and Distance from 200-Day Simple Moving Average of 135.59%.
The Company currently has ROA (Return on Assets) of -113.7 percent, Return on Equity (ROE) of -310.9 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.